Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
- PMID: 35799785
- PMCID: PMC9253603
- DOI: 10.3389/fimmu.2022.909027
Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
Abstract
Objective: Atezolizumab is becoming a significant therapy for non-small cell lung cancer (NSCLC), but its efficacy needs to be further improved. The aims of this study are to clarify the potency of atezolizumab-based therapy in advanced NSCLC patients with different clinical and molecular features, and to choose a better therapeutic regimen of atezolizumab to achieve more precise treatment in immunotherapy.
Methods: Randomized clinical trials (RCTs) in the Cochrane Library, PubMed, Embase Science Direct, and Google Scholar, together with major oncology conferences that compared atezolizumab with chemotherapy-based treatment for individuals with advanced NSCLC published prior to February 2022, were searched. Studies, bias risk assessment, and data extraction were selected by two independent authors. We extracted the basic features of the included studies, together with the 95% confidence interval (CI) and hazard ratios (HRs), from all patients and subgroups. The combined treatment data were assessed using the inverse variance weighting method.
Results: Seven RCTs including 4,859 patients were included. Our meta-analysis findings indicated that atezolizumab substantially enhanced OS (HR 0.82; 95% CI, 0.77-0.88; p < 0.00001) and PFS (HR 0.72; 95% CI, 0.61-0.85; p < 0.0001) in patients with advanced NSCLC compared with chemotherapy-based treatment. Atezolizumab substantially enhanced OS in patients aged <65 years old and 65-74 years old, those with wild-type EGFR, those without liver metastases, active or previous smokers, white patients and those with TC3 or IC3, TC2/3 or IC2/3, TC1/2/3 or IC1/2/3, and TC0 and IC0, but not in patients aged ≥75 years, never smokers, those with liver metastases, those with EGFR mutant, Asians, Black or African Americans, or those with TC1/2 or IC1/2. Patients with advanced NSCLC who received atezolizumab showed OS improvement regardless of sex (male or female), histological type (non-squamous or squamous NSCLC), performance status (0 or 1), and line of treatment (1st-line therapy or ≥2nd-line therapy). Subgroup analysis revealed that male individuals, those with non-squamous NSCLC, those with PS 1, active or previous smokers, and those with wild-type EGFR, TC3 or IC3, and TC1/2/3 or IC1/2/3 achieved OS benefit from atezolizumab treatment not related to the treatment line and treatment regimen.
Conclusions: Age group, smoking history, liver metastasis status, EGFR mutation status, race, and PD-L1 expression can be used to predict the potency of atezolizumab and provide a better treatment regimen for patients with advanced NSCLC to achieve accurate and personalized treatment.
Keywords: atezolizumab; meta-analysis; non-small cell lung cancer; potency; predictor.
Copyright © 2022 Liu, Huo, and Chen.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features.Front Immunol. 2022 Apr 5;13:875093. doi: 10.3389/fimmu.2022.875093. eCollection 2022. Front Immunol. 2022. PMID: 35479081 Free PMC article.
-
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10. Lancet. 2016. PMID: 26970723 Clinical Trial.
-
Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics.BMC Cancer. 2023 May 19;23(1):458. doi: 10.1186/s12885-023-10959-3. BMC Cancer. 2023. PMID: 37202730 Free PMC article.
-
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2021 Mar 18;3:CD010383. doi: 10.1002/14651858.CD010383.pub3. PMID: 27223332 Updated. Review.
-
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.Medicine (Baltimore). 2018 Aug;97(33):e11936. doi: 10.1097/MD.0000000000011936. Medicine (Baltimore). 2018. PMID: 30113497 Free PMC article. Review.
Cited by
-
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD015495. doi: 10.1002/14651858.CD015495. Cochrane Database Syst Rev. 2024. PMID: 39136258 Review.
-
Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis.Integr Cancer Ther. 2023 Jan-Dec;22:15347354231164584. doi: 10.1177/15347354231164584. Integr Cancer Ther. 2023. PMID: 36998207 Free PMC article.
-
Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging.Front Oncol. 2022 Oct 26;12:1017737. doi: 10.3389/fonc.2022.1017737. eCollection 2022. Front Oncol. 2022. PMID: 36387113 Free PMC article.
-
Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report.Front Oncol. 2022 Aug 11;12:937282. doi: 10.3389/fonc.2022.937282. eCollection 2022. Front Oncol. 2022. PMID: 36033496 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous